A recent study has shown that the addition of an anti‐PD‐1 antibody, pembrolizumab, to AMR for relapsed SCLC could afford a remarkable ORR of 52% and PFS rate of 14.4% at one year,19 indicating the promising effect of AMR when combined with ICIs. The gene discussed is PDCD1; the disease is small cell lung carcinoma.